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Highlights: 
 Routine performance of upper endoscopy does not significantly 
increase diagnostic yield for GI-GVHD. 
 Diarrhoea and advanced age are the only predictors for identifying 
histological GVHD in patients suspected of having GI-GVHD. 
 Of the patients who are ultimately treated for GI-GVHD, only 74% 
have GVHD confirmed on biopsy, thus highlighting a need for 
improved diagnostic techniques. 
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ABSTRACT 
Background / Aim:  
Acute gastrointestinal graft versus host disease (GI-GVHD) following haematopoietic 
progenitor cell transplantation (HPCT) is a common and life-threatening 
complication. Endoscopic biopsy of the gastrointestinal tract is required for 
diagnosis. However, clear evidence to optimise this diagnostic approach is lacking, 
leading to variation in diagnostic sensitivity between institutions. We aimed to 
assess the clinical, endoscopic and histological findings of endoscopies performed for 
suspected acute GI-GVHD at our institution to better define the optimal use of this 
strategy. 
Methods: 
We performed a retrospective cohort study of adults who had undergone endoscopy 
for suspected acute GI-GVHD within 180 days following allogeneic HPCT for 
haematological malignancy between 2011-2016. Details included: symptoms at time 
of referral for endoscopy, type of procedure performed, macroscopic findings on 
endoscopy, and histological findings following gut biopsy. Correlation was made with 
clinical GVHD severity scores. Sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) were calculated and compared for each 
procedure. Predictors of histological GVHD and overall survival were also compared. 
Results: 
Of the 123 patients included, acute GI-GVHD occurred in 59 (48%). Lower endoscopy 
demonstrated greater sensitivity than upper endoscopy (50% vs. 39%). Single upper 
endoscopy for upper symptoms alone had the lowest yield of GI-GVHD (14%). 
Combination upper and lower endoscopy demonstrated strong histological 
concordance between upper and lower procedures. The addition of upper 
endoscopy to lower endoscopy only identified an extra 2 (4%) cases of GVHD. 
Advanced age and the presence of lower GIT symptoms were the only pre-
endoscopy predictors of histological GVHD on multivariate analysis. Patients with 
isolated upper histological GVHD showed similar survival to patients with negative 
biopsies. Endoscopy and biopsy only identified 74% of those ultimately requiring 
treatment for acute GI-GVHD. 
Conclusion: 
Acute GI-GVHD remains a clinical diagnosis supported by available histological 
evidence. Isolated upper gastrointestinal GVHD is rare, and in the absence of lower 
GIT symptoms routine upper endoscopy does not significantly improve diagnostic 
yield for histological GVHD. Overall, endoscopy and biopsy underdiagnoses 26% of 
clinical GI-GVHD, highlighting a need for research into novel diagnostic strategies. 
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INTRODUCTION 
Acute gastrointestinal graft versus host disease (GI-GVHD) is a common and 
potentially life-threatening early complication following haematopoietic progenitor 
cell transplantation (HPCT). GI-GVHD is characterised by donor T-cell mediated 
invasion and inflammation of the gastrointestinal tract (1, 2), and the cardinal 
histological feature is cellular apoptosis. Symptoms include profuse diarrhoea, 
abdominal pain, and bleeding or perforation in severe cases. Clinical diagnosis of GI-
GVHD is often confounded by other conditions that produce similar symptoms; such 
as gastrointestinal infection from clostridium difficile or cytomegalovirus (CMV) 
reactivation, or direct gut toxicity from conditioning chemotherapy.  
The accepted standard diagnostic method for GI-GVHD is endoscopic visualisation 
and biopsy of the gastrointestinal tract (GIT), however the utility of this approach is 
influenced by numerous variables. Patchy GIT distribution of GI-GVHD may cause 
sampling error, as affected areas (such as the small bowel or proximal colon) may be 
inaccessible for biopsy. Performing biopsies only in macroscopically abnormal tissue 
may miss GI-GVHD, as up to 60% of macroscopically normal gut demonstrates 
histological GVHD (3, 4). Histological features of GI-GVHD can be non-specific, are 
highly reliant on the exclusion of confounding diagnoses such as CMV reactivation, 
and histological grade not appear to correlate with clinical severity (3, 5, 6). Less well 
evaluated are the potential confounding influences of clinical findings and 
management upon diagnostic yield of endoscopy and biopsy. The severity 
(Glucksberg stage and grade) and location (upper or lower GIT) of symptoms likely 
influences the decision to perform endoscopy, and the choice of procedures 
performed (upper or lower endoscopy, or both). 
Prospective studies (3, 4) of endoscopy in symptomatic patients included routine 
biopsy of GIT sites that were not macroscopically suspected of being involved by GI-
GVHD, in addition to macroscopically abnormal lesions. These data suggest that 
when using this approach GI-GVHD can be histologically identified in 60-88% of 
patients, with greater yield in lower endoscopy (80-90%) compared with upper 
endoscopy (60-70%), and greatest yield in combination upper and lower endoscopy 
(>90%). Retrospective data, assessing endoscopy performed only in the presence of 
clinical suspicion, demonstrate diagnostic yields in upper (27-84%) and lower 
endoscopy (50-80%) generally less than those seen in the prospective trials (7-10). 
Whether the greater diagnostic yield of histological GVHD identified in prospective 
trials correlates with improved response to anti-GVHD treatment, or survival, 
remains unknown.  
For these reasons, practice regarding initiation of endoscopy (at onset of early stage 
versus moderate-severe stage clinical GVHD, or at defined time points in 
asymptomatic patients), choice of procedures (single versus combined upper and 
lower endoscopy) and biopsy sites (limited versus extensive) differs between 
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transplant institutions. Against this background, we aimed to retrospectively assess 
all patients treated in our institution who underwent endoscopic biopsy for 
suspected acute GI-GVHD post-HPCT, and compare the clinical, endoscopic and 
histological findings to evaluate the performance of this diagnostic strategy.  
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MATERIALS AND METHODS 
Population details 
Consecutive adult patients who underwent matched sibling or volunteer unrelated 
allogeneic HPCT for haematological malignancy, or donor lymphocyte reinfusion 
(DLI) for post-HPCT relapse, between January 2011 and December 2016 were 
identified from an institutional database. All patients who underwent upper and/or 
lower endoscopy during the first 180 days post-HPCT (D+180) were then identified 
from a separate database detailing all endoscopic procedures performed during this 
period.  
Data pertaining to only the first endoscopic procedure prior to D+180 were included 
for assessment. Details included: clinical findings (symptoms) and severity at the 
time of referral for endoscopy, type of procedure performed, macroscopic findings 
on endoscopy, and histological findings following gut biopsy. Correlation was made 
with the incidence of a final clinical diagnosis of GI-GVHD, defined if the treating 
physician had documented GI-GVHD in the medical record as the final clinical 
diagnosis, and if the episode resulted in the patient being treated for acute GI-GVHD 
using a minimum of prednisone 1-2mg/kg/day. 
 
HPCT details 
All patients underwent T-cell replete HPCT. Myeloablative conditioning (MAC) 
regimens included cyclophosphamide 60mg/kg/day D-5 and D-4, plus total body 
irradiation 2Gy bd D-3 to D-1 (Cy/TBI). Reduced intensity conditioning (RIC) regimens 
included: fludarabine 25mg/m2 D-7 to D-3 plus melphalan 120mg/m2 D-2 (Flu-Mel). 
Non-myeloablative conditioning (NMAC) regimens included fludarabine 25mg/m2 D-
8 to D-4 plus cyclophosphamide 60mg/kg/day D-3 and D-2 (Flu-Cy) and fludarabine 
30mg/m2 D-4 to D-2 plus total body irradiation 2Gy D-1 (Flu-TBI). GVHD prophylaxis 
for MAC and RIC transplants consisted of intravenous cyclosporine A (CsA), plus D+1, 
+3, +6 and +11 methotrexate. GVHD prophylaxis for NMAC transplants included oral 
CsA plus mycophenolate mofetil (MMF).   
 
Definitions 
All patients undertaking endoscopy evaluation were clinically suspected to have GI-
GVHD. Symptoms leading to referral for endoscopy were defined as either upper 
(any / all of nausea, vomiting, anorexia), lower (any / all of diarrhoea, abdominal 
pain / cramps, ileus, perforation, fresh bleeding per rectum), or both. The clinical 
severity of suspected GVHD was defined as per modified Glucksberg criteria (5).  
Endoscopic procedures were defined as either upper (upper endoscopy, 
gastroscopy, oesophagoduodenoscopy), lower (rectosigmoidoscopy, flexible 
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sigmoidoscopy, colonoscopy) or combined (both upper and lower endoscopy). 
Capsule endoscopy was not included. The incidence of concurrent skin or liver GVHD 
occurring within 4 weeks prior to or following the endoscopy was recorded. The 
incidence of patients receiving prednisone at a dose of 0.5mg/kg or greater on the 
day of endoscopy was also recorded, as was the rationale for commencing 
prednisone. 
The decision regarding the choice of either upper, lower or combination endoscopies 
(including decision-making regarding rectosigimoidoscopy versus full colonoscopy 
for lower endoscopic procedures) was made by consultation between referring 
haematologist and performing gastroenterologist.  
Macroscopic findings were defined as either suspicious for GVHD (any / all of 
ulceration, oedema, inflammation, bleeding) or not suspicious for GVHD (normal or 
polyps). Biopsy sites were chosen during the procedure based on the clinical 
judgement of the performing gastroenterologist. 
Histological findings were defined as positive for GVHD if either a) the biopsy had 
been reported as GVHD, or b) the biopsy was reported as being suspicious of GVHD 
and CMV co-infection had been excluded. The histological grade of GVHD (Grade I-
IV), where reported, was included as per previously defined criteria (3, 6). The final 
clinical diagnosis was defined as per the documentation in the medical record.  
 
Statistical analysis 
The incidence of histological GVHD was used to define the diagnostic sensitivity of 
individual procedures. Fisher’s exact test was used for assessment of 2x2 
contingency tables for categorical variables. Sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV) were calculated for each 
contingency table. A stepwise logistic regression model was used for multivariate 
analysis of co-variables that were significantly associated with histological GVHD. 
Survival analysis was calculated using the Kaplan-Meier method. Statistical analysis 
was performed using Prism 7 (GraphPad, California USA) and Stata 12 (Statacorp, 
Texas USA).  
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RESULTS 
Population characteristics 
Of a total 551 HPCT procedures performed during the period, 123 patients (22%) 
underwent endoscopic evaluation for clinically suspected GVHD prior to D+180 post-
HPCT and were included for analysis. Baseline characteristics are summarised in 
Table 1.  
 
Clinical, endoscopic and histological findings 
In the 123 patients who underwent endoscopic investigation prior to D+180 post 
HPCT, a total of 111 upper and 109 endoscopies were performed, at a median 43 
days post HPCT or DLI (range 9-180 days). Details are summarised in Table 2. 79% of 
patients underwent combination endoscopy. All patients had at least one biopsy 
taken during their upper and / or lower endoscopies. At the time of endoscopy, 42 
(34%) patients had been diagnosed with GVHD of skin and/or liver in the preceding 4 
weeks, and 40 (33%) patients were still receiving prednisone at a minimum dose of 
0.5mg/kg/day. 
The most common clinical indication for endoscopy was concurrent upper and lower 
symptoms (n=62; 50%), with isolated lower symptoms alone (n=44; 36%) or upper 
symptoms alone less frequent (n=17; 14%). Single upper endoscopy was 
predominantly performed for isolated upper symptoms (71%), single lower 
endoscopy predominantly for isolated lower symptoms (75%), and combination 
endoscopy predominantly for combined symptoms (56%). In terms of symptom 
severity, the median Glucksberg clinical stage was 1 (range 0-4), with 17 (14%) 
patients classified as severe (Stage III-IV). 
Macroscopic GVHD was reported in 74 (60%) of endoscopies overall, but at similarly 
lower rates for single upper or single lower procedures (43% vs. 44% respectively). In 
those who underwent combination endoscopy, only 23% had both upper and lower 
macroscopic GVHD.  
Histological GVHD (Table 3) was identified in 59 patients, representing 48% of the 
study cohort and 11% of total HPCT recipients during this timeframe. Histological 
GVHD was more common in lower or combination endoscopy than in upper 
endoscopy (50%, 50% and 39% respectively). Sigmoid (48%) and rectum (45%) were 
the most commonly involved sites, compared to duodenum (38%) and stomach 
(27%); in all four patients who underwent full colonoscopy, proximal and distal colon 
were simultaneously involved. Notably, isolated upper histological GVHD was rare, 
identified in only 4% of all upper endoscopies (14% of single upper endoscopy), 
compared with simultaneous upper and lower histological GVHD (41% of combined 
endoscopies), or isolated lower histological GVHD (15% of all lower endoscopies).  
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A final clinical diagnosis of GI-GVHD was reached in 76 (62%) patients overall; the 
final clinical diagnosis in the remaining 47 patients was either CMV disease (5; 4%), 
C.Difficile gastroenteritis (5; 4%), or drug-related diarrhoea (37; 30%). Of the 76 GI-
GVHD patients, 56 (74%) had histologically confirmed GVHD on endoscopic biopsy. 
All 76 patients were treated for GI-GVHD based upon their gastrointestinal 
symptoms, using either prednisone 1mg/kg or equivalent or greater. The presence of 
co-existing skin and/or liver GVHD, occurring within four weeks prior to or following 
endoscopy, was similar in patients with or without histological GI-GVHD (50% vs. 
45%; p=0.79).  
Of the 123 patients, 36 (29%) underwent a repeat endoscopic biopsy within 30 days 
following their original endoscopy. Histological GVHD was identified in 19 (53%) of 
those patients. Repeat endoscopy occurred more frequently in those who had been 
treated for a final clinical diagnosis of GI-GVHD compared to those with alternative 
final clinical diagnoses (42% vs. 9%; p=0.0001), however histological GVHD in the 
repeat biopsies was reported at a similar frequency between these two groups (50% 
vs. 75%; p=0.60).  
 
Statistical analysis 
Statistical analysis was undertaken to identify variables statistically associated with 
histological GVHD, and variables that improved the diagnostic sensitivity (48%), 
specificity, PPV and NPV of endoscopic procedures.  
Pre-endoscopy, lower gastrointestinal symptoms showed greater sensitivity than 
upper symptoms (97% vs. 63%) and improved NPV (88% vs. 49%). In those patients 
who had upper symptoms at the time of upper endoscopy, almost all (94%) had co-
existing lower symptoms; no histological GVHD was identified in the remaining 6% 
without co-existing lower symptoms. Advanced clinical stage (Glucksberg III-IV) 
demonstrated poor sensitivity (25-28%) but high specificity (96%) and PPV (80-85%) 
for histological GVHD in all endoscopies. Sensitivity was not significantly affected by 
prednisone usage prior to endoscopy (53%) or recent skin / liver GVHD (49%), 
however both showed high PPV for a final clinical diagnosis of GI-GVHD (100% and 
93% respectively). 
During endoscopy, macroscopic GIT abnormalities showed a high sensitivity (80%) 
for histological GVHD across all endoscopies. However, macroscopic findings in 
upper endoscopy were less predictive of histological GVHD than those in lower or 
combination endoscopy (sensitivity 53%, 71% and 79% respectively). In combination 
endoscopy, there was a strong correlation between histological findings at upper 
versus lower biopsy sites: 95% of patients with upper GVHD had co-existing lower 
GVHD identified, and 85% of patients with lower GVHD had co-existing upper GVHD 
identified.  
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Histological grade correlated poorly with advanced clinical stage grade in proven 
GVHD, with PPV of advanced findings in both categories only 47%. However, 
correlation between early stage / low grade GVHD appeared stronger, with 
specificity 80% and NPV 73%. 
A clinical diagnosis of GVHD demonstrated PPV 74% and NPV 94% for histological 
GVHD. 
 
Multivariate analysis 
Logistic regression analysis was performed to identify pre-endoscopy predictors of 
histological GVHD (Table 4). The only factors remaining significant on multivariate 
analysis were lower symptoms (diarrhoea OR 8.13, p=0.01; cramps OR 2.59, p=0.03) 
and age at HPCT (OR 1.06, p<0.001). Notably, the use of prednisone pre-endoscopy 
was not associated with a subsequent diagnosis of histological GVHD.  
 
Survival 
At a median 24 months’ follow-up, overall survival (OS) for the entire cohort is 
56.9%, with median OS 3.6 years for the entire cohort.  
Patients with positive clinical and histological diagnosis of GI-GVHD showed 
significantly inferior survival compared to patients with clinical and histological 
diagnoses negative for GI-GVHD (1-yr OS 48.2% vs. 88.6%; p=0.001, Hazard Ratio 
[HR] 0.71 [0.58-0.87]) (Figure 1). Although patients with discordant final clinical and 
histological diagnoses showed 1-yr OS of 65.0-66.7%, their OS was still significantly 
inferior to those with negative clinical and histological diagnoses.  
Figure 2 depicts survival analysis based upon the site of histological GVHD 
involvement. Notably, patients with isolated histological upper GVHD had similar OS 
to patients who had negative histology from all biopsy sites (1-yr OS 75.0% and 
81.2% respectively), compared to inferior survival seen in patients with either 
isolated lower histological GVHD or combined upper and lower histological GVHD (1-
yr OS 37.5% and 51.2% respectively; p=0.02, HR 0.81 [0.67-0.97]). 
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DISCUSSION 
This study retrospectively compared the clinical, endoscopic and histological findings 
in post-HPCT patients to assess the performance of the current accepted diagnostic 
strategy for defining GI-GVHD. Results from our cohort suggest that histological 
GVHD is only present in 40-50% of those evaluated with endoscopy and biopsy, that 
lower symptoms and older age are the only pre-endoscopy variables significantly 
associated with histological GVHD, and that this diagnostic strategy only identifies 
74% of those patients ultimately treated for GI-GVHD. 
We report similar diagnostic sensitivity to those reported in other retrospective 
studies, but still inferior to those reported in prospective studies, where sensitivities 
approach 90%. The consistent disparity between retrospective and prospective 
studies is interesting and not easily explained, given that most institutions report a 
similar diagnostic approach predominantly using combination endoscopy, and 
include biopsies performed in macroscopically normal tissue. Rates in the true 
incidence of GI-GVHD may differ based upon institutional HPCT approach, and upon 
differences in the clinical threshold used for endoscopy referral. 
Our results suggest that the presence of lower gastrointestinal symptoms (such as 
diarrhoea, abdominal cramps and pain) is the only relevant predictor of 
subsequently identifying histological GVHD on endoscopy. This is not surprising, as 
GI-GVHD is classically manifested by lower abdominal symptoms. Severe lower 
symptoms were highly specific but insensitive, consistent with the experience severe 
cases account for a minority of GI-GVHD. 
However, our results reinforce the poor predictive power of upper symptoms (and 
by extension, upper endoscopy) for histological GVHD, by showing that upper 
symptoms were only predictive when associated with co-existing lower symptoms. 
Upper endoscopy rarely identified discordant findings compared to concurrent lower 
endoscopy, and only identified an extra 2 (4%) cases of histological GVHD in 
combination endoscopy. Single upper endoscopy for upper symptoms alone showed 
the lowest diagnostic sensitivity (14%) for all procedures. Our findings confirm that 
the distal colon is the site most commonly involved by GI-GVHD, but also illustrate 
that it is rare for the proximal GIT to be the sole site involved.  
Furthermore, clinical severity correlated poorly with reported histological grade, as 
reported in other studies (3, 4). Possible explanations include sampling error due to 
patchy bowel involvement by GVHD, or the possibility that histological findings 
reflect the subsequent “effector” phase of GVHD, which may not be representative 
of GI-GVHD overall severity. Regardless, the relevance of histological grade in the 
current context appears questionable. 
Interestingly, the presence of upper histological GVHD did not appear to confer 
adverse survival compared to patients with negative biopsies. This analysis is limited 
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by the low incidence of isolated upper GVHD, but may suggest a better than 
expected prognosis when compared to patients with lower GIT GVHD. 
A key finding is that early introduction of prednisone did not negatively impact upon 
the likelihood of identifying histological GVHD. This validates ours and other 
institutions’ practice of not delaying steroid treatment while awaiting confirmatory 
pathology in patients with a strong clinical suspicion of GI-GVHD and a lack of 
alternate diagnoses.  
Most importantly, our study found that endoscopy and biopsy identifies histological 
GVHD in only 74% of those ultimately requiring treatment for a clinical diagnosis of 
GI-GVHD. To our knowledge this finding has not previously been reported, and is a 
consistent finding in our cohort across different combinations of symptoms and 
endoscopy procedures. The remaining 26% of patients treated for GI-GVHD despite 
negative biopsies, best characterised as “discordant” cases, show superior OS 
compared to “true positive” cases yet inferior OS compared to “true negative” cases 
(Figure 1). 
The explanation for this discrepancy is not clear. Co-existing GVHD in other organs 
such as skin or liver occurred at similar rates between groups, and repeat endoscopic 
biopsies (where performed) identified histological GVHD at similar rates between 
groups. Furthermore, the definitions used for histological and clinical diagnosis 
appear sufficiently robust as to preclude spurious “over-diagnosis” by clinicians or 
pathologists in our centre. While the survival difference may represent adverse 
effects of GVHD therapy in patients not truly requiring therapy, it may plausibly 
instead illustrate a population with GI-GVHD that is more responsive to therapy. 
Nevertheless, regardless of whether 26% of clinical GI-GVHD is “clinically over-
diagnosed” or “histologically under-diagnosed,” the reality is that this perfectly 
illustrates a common conundrum in transplantation – the HPCT patient with 
moderate-severe gastrointestinal symptoms for whom no reasonable diagnosis 
other than GI-GVHD can be established, despite best practice diagnostic techniques 
and expertise. Given “discordant” cases have inferior survival to “true negative” 
cases, there is clearly a need to develop improved diagnostic strategies to better 
identify GI-GVHD. 
A variety of novel techniques are being developed but are not yet ready for universal 
incorporation into routine practice. Diagnostic molecular imaging using FDG-PET is 
sensitive for GI-GVHD but nonspecific, and may only have a role in excluding GI-
GVHD or in targeting lesions for subsequent endoscopic biopsy (11-13). Blood-based 
measurement of cytokine biomarkers such as ST2, IL2Ra and TNFR1 has been shown 
to predict response to anti-GVHD therapy (14-16), however a universally adoptable 
cytokine panel with high PPV for GVHD has not yet been demonstrated.  
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The main limitation of our study is its retrospective design, although this is not 
dissimilar to other studies in this field. Statistical assessments involving the final 
clinical diagnosis of GI-GVHD may be subject to observer error due to the judgement 
of individual treating clinicians at the time, which is true of all studies assessing 
clinical diagnoses.  
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CONCLUSION 
Endoscopy and biopsy remains a valid diagnostic method for GI-GVHD, in 
combination with clinical judgement. Lower gastrointestinal symptoms and 
advanced age are the only significant pre-endoscopy variables for predicting 
histological GVHD. Isolated upper gastrointestinal GVHD is rare, particularly in the 
absence of lower gastrointestinal symptoms, and shows similar 1-yr OS compared to 
patients who have negative biopsies. Therefore, upper endoscopy could reasonably 
be omitted during investigation for GI-GVHD, except where alternative diagnoses are 
suspected. Overall, endoscopy and biopsy underdiagnoses 26% of clinical GI-GVHD, 
highlighting a need for research into novel diagnostic strategies. 
  
Page 15 of 23
ACKNOWLEDGEMENTS 
The authors declare no competing conflicts of interest. 
 
 
 
 
  
Page 16 of 23
References. 
 
1. Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a 
bench-to-bedside update. Blood. 2014;124(3):363-73. 
2. Henden AS, Hill GR. Cytokines in Graft-versus-Host Disease. J Immunol. 
2015;194(10):4604-12. 
3. Thompson B, Salzman D, Steinhauer J, Lazenby AJ, Wilcox CM. Prospective 
endoscopic evaluation for gastrointestinal graft-versus-host disease: 
determination of the best diagnostic approach. Bone marrow transplantation. 
2006;38(5):371-6. 
4. Aslanian H, Chander B, Robert M, Cooper D, Proctor D, Seropian S, et al. 
Prospective evaluation of acute graft-versus-host disease. Digestive diseases and 
sciences. 2012;57(3):720-5. 
5. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et 
al. 1994 Consensus Conference on Acute GVHD Grading. Bone marrow 
transplantation. 1995;15(6):825-8. 
6. Sale GE, Shulman HM. The Pathology of bone marrow transplantation. 
New York: Masson Pub. USA; 1984. ix, 265 p. p. 
7. Cloutier J, Wall DA, Paulsen K, Bernstein CN. Upper Versus Lower 
Endoscopy in the Diagnosis of Graft-Versus-Host Disease. Journal of clinical 
gastroenterology. 2016. 
8. Ross WA, Ghosh S, Dekovich AA, Liu S, Ayers GD, Cleary KR, et al. 
Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: 
rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. 
The American journal of gastroenterology. 2008;103(4):982-9. 
9. Lee KJ, Choi SJ, Yang HR, Chang JY, Kang HJ, Shin HY, et al. Stepwise 
Endoscopy Based on Sigmoidoscopy in Evaluating Pediatric Graft-versus-Host 
Disease. Pediatric gastroenterology, hepatology & nutrition. 2016;19(1):29-37. 
10. Terdiman JP, Linker CA, Ries CA, Damon LE, Rugo HS, Ostroff JW. The role 
of endoscopic evaluation in patients with suspected intestinal graft-versus-host 
disease after allogeneic bone-marrow transplantation. Endoscopy. 
1996;28(8):680-5. 
11. Martin Cherk SP, Stuart Roberts, Gregor Brown, Sharon Avery, Patricia 
Walker, Catriona McLean, Kenneth Yap, Andrew Spencer, and Victor Kalff. Non 
invasive evaluation of acute graft versus host disease of the gastrointestinal tract 
following allogeneic haemopoietic stem cell transplantation using FDG PET. J 
Nucl Med. 2012;May(53:1359). 
12. Marie Lacombe MM, Thomas Eugene, Catherine Ansquer, Francoise 
Kraeber-Bodere, Thomas Carlier, Thierry Guillaume, Patrice Chevallier, Jacques 
Delaunay, and Caroline Bodet-Milin. FDG-PET/CT for the detection of 
gastrointestinal graft-versus-host disease (GVHD) after allogeneic hematopoietic 
stem cell transplantation (allo-HSCT). J Nucl Med 2011;May(52:1877). 
13. Bodet-Milin C, Lacombe M, Malard F, Lestang E, Cahu X, Chevallier P, et al. 
18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot 
study. Bone marrow transplantation. 2014;49(1):131-7. 
14. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, Ferrara JL, et al. 
Acute graft-versus-host disease biomarkers measured during therapy can 
predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials 
Network study. Blood. 2012;119(16):3854-60. 
Page 17 of 23
15. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as 
a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl 
J Med. 2013;369(6):529-39. 
16. Ali AM, DiPersio JF, Schroeder MA. The Role of Biomarkers in the 
Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A 
Systematic Review. Biol Blood Marrow Transplant. 2016;22(9):1552-64. 
 
 
  
Page 18 of 23
FIGURE 1: OS COMPARING CLINICAL GVHD VERSUS HISTOLOGICAL GVHD. 
 
 
Key: Clin Pos Histo Pos (Histological GVHD and final clinical diagnosis of GI-GVHD), 
Clin Pos Histo Neg (Histological GVHD but an alternative final clinical diagnosis), Clin 
Neg Histo Pos (Histology negative for GVHD but final clinical diagnosis was GI-
GVHD), Clin Neg Histo Neg (Neither histological GVHD nor a final clinical diagnosis of 
GI-GVHD). 
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FIGURE 2: OS COMPARING UPPER VERSUS LOWER GIT INVOLVEMENT. 
 
 
Key: Upper and Lower (both upper and lower biopsy sites reported as histological 
GVHD), Lower only (Lower histological GVHD but no upper histological GVHD), Upper 
only (Upper histological GVHD but no lower histological GVHD), Neither (No upper or 
lower biopsies reported as GVHD). 
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TABLE 1: BASELINE CHARACTERISTICS 
Characteristic Number (%) 
Number 123 
Median age (range) 52 (16-69) 
Male sex 63% 
Diagnosis:  
- Acute Myeloid Leukaemia 50 (40%) 
- Acute Lymphoblastic Leukaemia 29 (24%) 
- Myelodysplastic syndrome / Myeloproliferative 
Neoplasms 
28 (23%) 
- Lymphoproliferative neoplasms 16 (13%) 
  
Donor:  
- Unrelated 86 (70%) 
- Matched sibling 37 (30%) 
  
Conditioning regimen:  
- Myeloablative 46 (37%) 
- Reduced intensity 71 (58%) 
- Non-myeloablative 6 (5%) 
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TABLE 2: ENDOSCOPY PROCEDURES PERFORMED. 
Findings Number (%) 
Total patients  123 
  
Procedure type:  
Upper endoscopy alone 14 (11%) 
Lower endoscopy alone 12 (10%) 
Combination upper and lower endoscopy 97 (79%) 
  
Procedure description:  
Upper endoscopy 111 
- Oesophagogastroduodenoscopy (OGD) 111 (100%) 
Lower endoscopy 109 
- Rectosigmoidoscopy 105 (96%) 
- Colonoscopy 4 (4%) 
  
Biopsies performed:  
Upper biopsy 110 (99%) 
Lower biopsy 109 (100%) 
Both upper and lower biopsies 96 (99%*) 
*Expressed as a proportion of those who underwent combination endoscopy. 
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TABLE 3: HISTOLOGICAL GVHD. 
Histological GVHD Number (%) 
Total patients 123 
Histological GVHD at any biopsy site 59 (48%) 
- Histological Grade III-IV GVHD 19 (15%) 
  
Upper biopsies 110 
GVHD 43 (39%) 
 - Isolated upper GVHD 4 (4%) 
  
Lower biopsies 109 
GVHD 55 (50%) 
 - Isolated lower GVHD 16 (15%) 
  
Combination biopsy 96 
GVHD 48 (50%) 
 - upper GVHD 2 (2%) 
 - lower GVHD 7 (7%) 
 - both upper and lower GVHD 39 (41%) 
 
 
TABLE 4: UNIVARIATE ANALYSIS OF PREDICTORS FOR HISTOLOGICAL GVHD. 
Variable p-value 
Age <0.001 
Sex 0.42 
Donor type 0.12 
CMV match 0.47 
Conditioning 0.002 
Prednisone >0.5mg/kg on day of endoscopy 0.22 
Upper GI symptoms 0.60 
Lower GI symptoms 0.003 
 
Page 23 of 23
